BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) — The Transplant Company™, a leading precision medicine company focused on the discovery, development, and commercialization of ...

Ultra‑Sensitive, Non‑Invasive Surveillance Solution Expected to Launch Commercially in the U.S. in 2027 as Part of CareDx’s Transplant+ Precision Medicine Portfolio BRISBANE, Calif., February 12, 2026 ...

Long-Term Survivorship After Chimeric Antigen Receptor T-Cell Therapy for Hematologic Malignancies The CHAI platform extracted quantitative histomorphologic features from whole-slide images of ...

More than 17,000 individuals with cancer died from their malignancy within a year of their diagnosis during the COVID-19 pandemic than expected based on previous trends.

Relative Energy Deficiency in Sport (REDs) has various different risk factors, numerous signs and symptoms and is heavily influenced by one’s environment. Accordingly, there is no singular validated ...

Objective To assess whether post-authorisation studies registered with the European Medicines Agency (EMA) adhere to legislation and recommendations to publicly post study protocols and results.

Linda McMaken has 15+ years of experience as a writer and editor. She is a published author and skilled blogger about consumer finance. Eric's career includes extensive work in both public and ...